UBT251
UBT251
Evidence & Status
- Moderate Evidence
- Moderate
At a Glance
An investigational GLP-1/GIP/glucagon triple-agonist peptide with published randomized Phase 1a/1b and 24-week Phase 2 weight-management research.
Plain English
UBT251 is being studied for weight management. Early trials and a published 24-week Phase 2 trial reported weight reductions and gastrointestinal adverse events, generally mild to moderate in Phase 2. These findings cannot predict an individual's benefit, and longer-term efficacy and safety remain uncertain.
Overview
UBT251 is an investigational peptide agonist of GLP-1, GIP and glucagon receptors. A randomized, double-blind, placebo-controlled Phase 1a/1b publication studied subcutaneous administration, with safety and tolerability as primary endpoints. A published multicenter, randomized, double-blind, placebo-controlled Phase 2 trial studied 205 adults with overweight or obesity without type 2 diabetes for 24 weeks. These studies do not establish an approved obesity treatment or long-term efficacy and safety.
Research Summary
The Phase 1a study evaluated single ascending subcutaneous doses; the Phase 1b study evaluated 12 weeks of once-weekly treatment in participants with overweight or obesity without diabetes. In the reported active-dose groups, mean weight reductions ranged from 8.96 to 13.48 kg, compared with a 1.57 kg increase with placebo. Laboratory investigations, decreased appetite and gastrointestinal adverse events were the most commonly reported adverse effects. Approximately linear pharmacokinetics were reported within the studied 1.0–6.0 mg range; this is study-specific, not a dosing recommendation. A subsequent published multicenter, randomized, double-blind, placebo-controlled Phase 2 trial studied 205 adults with overweight or obesity without type 2 diabetes for 24 weeks. At week 24, least-squares mean body-weight reductions ranged from 13.6% to 19.7% across UBT251 groups, compared with 2.0% with placebo. Gastrointestinal adverse events were commonly reported and generally mild to moderate. Longer-term efficacy and safety remain uncertain; these trial findings do not establish individual outcomes or an approved treatment.
Research Areas
- Obesity research
- Weight management
- GLP-1/GIP/glucagon receptor research
Safety & Risks
Reported Side Effects
- Gastrointestinal adverse events
- Decreased appetite
Legal Status by Region
- United States
- Investigational research; no approved clinical use is asserted by this record.
- United Kingdom
- Current authorization status not established in this record.
- Australia
- Current authorization status not established in this record.
- Canada
- Current authorization status not established in this record.
Citations & Sources
- Safety, Pharmacokinetics and Pharmacodynamics of the GLP-1/GIP/GCG Receptor Agonist UBT251 Injection: A Randomized, Placebo-Controlled Phase 1a/1b Study.
Diabetes, Obesity and Metabolism · 2026
PMID 42712041 · DOI 10.1111/dom.71327
- UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with overweight or obesity: A multicenter, randomized phase 2 trial
Cell Metabolism · 2026
PMID 42843337 · DOI 10.1016/j.cmet.2026.09.021